Merck, Abbott Lab, Europroteome, Spectral Genomics, Affymetrix, Zymark, Caliper Life Sciences, Epoch Biosciences, Lynx Therapeutics, Orchid, Illumina, Broad Institute | GenomeWeb

Merck Invests $10M in Decode as Companies Pen PGx Collaboration

Merck has bought $10 million worth of Decode shares, and the companies have begun a 7-year collaboration to perform pharmacogenomics studies, Decode said last week.

Terms of the deal call for Decode to run clinical trials of certain Merck compounds. Depending on trial results, Decode and Merck may also develop pharmacogenomic-based tests to identify patients who would benefit from a Merck therapy.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.